03320.HK
China Resources Pharmaceutical Group Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 4.64
+3.11%Year over year
Reported trailing growth
- Revenue
- +8.8%
- EBITDA
- +8.0%
- EBIT
- +0.1%
- EPS
- +56.3%
- Free cash flow
- +0.8%
- Operating cash flow
- -0.8%
Forward estimates
Based on analyst estimates
- Revenue
- +9.2%
- EBITDA
- -23.9%
- EPS
- +12.9%
Three-year CAGR
- Revenue
- +10.4%
- EBITDA
- +10.9%
- EBIT
- +13.6%
- Net income
- +7.3%
- EPS
- +9.4%
- Free cash flow
- +41.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026